A new study, led by Dr. David Fuller, shows restoration of cardio-respiratory function following neonatal AAV9 gene therapy in a rat model of Pompe disease. Since central nervous system disease substrates are missed using enzyme replacement therapy, this approach mitigates critical disease causing neuropathology. Check out the full publication…
Continuing UF College of Medicine’s revolutionary work developing the adeno-associated virus (AAV) vector, Dr. Barry Byrne, M.D., Ph.D., Associate Chair of Pediatrics and Director of the Powell Gene Therapy Center, will serve as President of the American Society of Gene and Cell Therapy (ASGCT) during the society’s 30th anniversary year …
BREATHE member Dr. Barry Byrne, director of the UF Powell Center for Rare Disease Research and Therapy and a gene therapy pioneer with about 23 patents in the field, will be inducted into the 2024 class of the Florida Inventors Hall of Fame in the fall, the organization announced May 30.
Two proposals from the University of Florida College of Medicine — one that aims to build a fully immersive digital replica of operating rooms and intensive care units, and another that will enhance and expand programs in cell and gene therapy — have received $3.5 million from the…
Dave Fuller, Professor of Physical Therapy and BREATHE Associate Director, and Barry Byrne, Associate Chair of Pediatrics, Director of the Powell Gene Therapy Center, and BREATHE member, received a 5-year NIH R01 award to continue their work on gene therapy for …
